Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Yes, you do make a lot of sense... thanks
I guess we have no way to estimate how much that would be...
Let's wait and see... though I am afraid FDA is going to take its sweet time...
Thanks MM, very interesting read
Since I guess manufacturing is being made by a third party (as I think that is the case)I wonder how that can benefit APRI
Negativity and pessimism dont help PPS and therefore shareholders.
Very hard to understand people (supposed to be shareholders) who day and night dont miss a chance to make Fear Uncertainty & Doubt stay for good.
I am also frustrated, but I favor my own interests to whining and complaining (no matter how bad Mngmt might be)or at least that is not my only topic
Sorry Shanka, I liked the article
Thx East, nice post for a break I had enough whining!!!
Even though news may not happened till the end of the quarter I bought some more... PPS is a bargain at this level and trying to time the market is almost an impossible task
Peregrine Launches PS-Targeting Clinical Imaging Program
Investigational New Drug Application Filed With the FDA to Advance Lead Imaging Candidate 124I-PGN650 Into Clinical Development; AACR Presentation Shows Increased Exposure of Phosphatidylserine (PS) Following Docetaxel Treatment Further Supporting Clinical Imaging, Diagnostic and Therapeutic Applications
Press Release: Peregrine Pharmaceuticals – 4 minutes 9 seconds ago
Companies:
Peregrine Pharmaceuticals Inc.
RELATED QUOTES
Symbol Price Change
PPHM 0.5401 0.00
TUSTIN, CA--(Marketwire -04/03/12)- Peregrine Pharmaceuticals, Inc. (NASDAQ: PPHM - News), a clinical-stage biopharmaceutical company developing first-in-class monoclonal antibodies for the treatment and diagnosis of cancer and infectious diseases, today announced that it has launched a program for its experimental phosphatidylserine (PS)-targeting molecular imaging candidate, 124I-PGN650, for the imaging of multiple solid tumor types. This program is highlighted with data presented yesterday at the Annual Meeting of the American Association for Cancer Research (AACR) and with the recent filing of an Investigational New Drug application with the United States Food and Drug Administration (FDA).
"We are very excited by the diagnostic imaging potential of our proprietary PS-targeting technology platform and feel that this addition to our clinical pipeline could hold considerable value. Molecular imaging agents represent a large and rapidly growing market. With improved personalized oncology therapies becoming a reality in recent years, there is a growing need for products that can quickly assess a patient's response to therapy and PGN650 has shown considerable promise in this area," said Steven W. King, president and chief executive officer of Peregrine. "Our initial goal for the PGN650 program is to further validate the broad nature of the PS-targeting platform. Results from this study may open the door for multiple applications including antibody drug conjugates (ADC), the ability of 124I-PGN650 to monitor the effectiveness of current standard cancer treatments, and the ability to potentially select patients that may do better in bavituximab based treatment regimens."
Data presented yesterday(1) at AACR demonstrated that a near infrared-labeled PS-targeting imaging agent (NIR-PGN650) was able to specifically identify and target multiple solid tumors. Data also showed that NIR-PGN650 could demonstrate a measurable increase in PS exposure in tumors following chemotherapy.
"The imaging clinical program brings an opportunity for rapid results since each patient can be independently evaluated and conclusions drawn in just a few weeks time unlike therapeutic studies that take considerable time for patient treatment and collective trial results to emerge," said Joseph Shan, vice president of clinical and regulatory of Peregrine. "At any point during the trial, successful images from the 12 anticipated patients in the study could provide a compelling rationale to expand the PS-targeting imaging platform into several promising new areas."
1. Presentation Title: Tumor detection and measurement of responses to chemotherapy using human phosphatidylserine targeting antibody fragments
Presentation Time: Monday, Apr 02, 2012, 1:00 PM - 5:00 PM
Location: McCormick Place West (Hall F), Poster Section 16
Poster Board Number: 25
Authors: Jian Gong(1), Rich Archer(1), Matthew Peacock(2), Christopher Hughes(2), Connie Chang(1), Bruce Freimark(1) 1. Peregrine Pharmaceuticals, Inc., Tustin, CA; 2. Univ. of California at Irvine, Irvine, CA
About 124I-PGN650
124I-PGN650 is a first-in-class phosphatidylserine (PS)-targeting F(ab')(2) fully human monoclonal antibody fragment joined to the PET imaging radio-isotope iodine-124 (124I) that represents a new approach to imaging cancer. PS is a molecule usually located inside the membrane of healthy cells, but "flips" and becomes exposed on the outside of cells that line tumor blood vessels, creating a specific target for the imaging of multiple solid tumor types. In preclinical studies, 124I-PGN650 accumulates in tumor vasculature and provides exceedingly clear in vivo tumor images. More information on Peregrine's Imaging Program can be found at http://www.peregrineinc.com/technology/ps-imaging.html
About Peregrine Pharmaceuticals
Peregrine Pharmaceuticals, Inc. is a biopharmaceutical company with a portfolio of innovative monoclonal antibodies in clinical trials for the treatment of cancer and serious viral infections. The company is pursuing multiple clinical programs in cancer and infectious diseases with its lead product candidate bavituximab and novel brain cancer agent Cotara®. Peregrine also has in-house cGMP manufacturing capabilities through its wholly-owned subsidiary Avid Bioservices, Inc. (www.avidbio.com), which provides development and biomanufacturing services for both Peregrine and outside customers. Additional information about Peregrine can be found at www.peregrineinc.com.
Safe Harbor Statement: Statements in this press release which are not purely historical, including statements regarding Peregrine Pharmaceuticals' intentions, hopes, beliefs, expectations, representations, projections, plans or predictions of the future are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. The forward-looking statements involve risks and uncertainties including, but not limited to, the risk that results of imaging clinical trials may not correlate to pre-clinical study results and the risk that the results randomized Phase II second-line NSCLC trial will not be consistent with results experienced in the earlier trials or support registration filings with the FDA, and the risk that Peregrine may not have or raise adequate financial resources to complete the planned clinical programs. Factors that could cause actual results to differ materially or otherwise adversely impact the company's ability to obtain regulatory approval for its product candidates include, but are not limited to, uncertainties associated with completing preclinical and clinical trials for our technologies; the early stage of product development; the significant costs to develop our products as all of our products are currently in development, preclinical studies or clinical trials; obtaining additional financing to support our operations and the development of our products; obtaining regulatory approval for our technologies; anticipated timing of regulatory filings and the potential success in gaining regulatory approval and complying with governmental regulations applicable to our business. Our business could be affected by a number of other factors, including the risk factors listed from time to time in the company's SEC reports including, but not limited to, the annual report on Form 10-K for the year ended April 30, 2011 and the quarterly report on Form 10-Q for the quarter ended January 31, 2012. The company cautions investors not to place undue reliance on the forward-looking statements contained in this press release. Peregrine Pharmaceuticals, Inc. disclaims any obligation, and does not undertake to update or revise any forward-looking statements in this press release.
Contact:
Christopher Keenan or Jay Carlson
Peregrine Pharmaceuticals, Inc.
(800) 987-8256
info@peregrineinc.com
Yeah.. the video is great but most had already been said at the last C.C.
By year end things will look pretty differently
IMHO
Why bring in the delisting issue when everyone knows that after the warning announcement delisting itself is quite a few months away. Already too many bad things goong on with PPHM... No need that one. Give us a break
<<Concurrently with the closing of this financing, the Company elected to its Board of Directors Dr. James Berglund>>
It seems J. Berglund has some experience in "eye caring""... spent the first twenty-one years of his career in the areas of eye care and eye care products..."
I wonder if that is related with ISCO cornea activities
http://www.epvc.com/data/Bios/vitae/Jim-Berglund.pdf
Jim Berglund
Managing Director
jberglund@epvc.com
Jim Berglund co-founded Enterprise Partners Venture Capital in 1985 as one of the first
venture firms focused on investing in Southern California technology and health care
companies. Over the past 20 years, Jim has been instrumental in establishing Southern
California as one of the country’s leading regions for venture backed technology
innovation, while at the same time building Enterprise Partners into the largest venture
firm headquartered in the region.
In his years with the firm, Jim has served as the lead on more than thirty portfolio
companies, including Primary Access Corporation, Elgar Electronics, Inc., Risk Data
Corporation. Accredited Home Lenders, Inc., Digital Style, Inc., Premier Laboratories,
Inc., IC Works, Inc., Captiva Software Corporation and Applied Digital Access, Inc.
Prior to co founding Enterprise Partners, Jim spent the first twenty-one years of his
career in the areas of eye care and eye care products, first with a successful private
optometric practice, then as President and Board Member of Central Laboratories, Inc.
and as General Manager of the Contact Lens Division of American Optical Corporation.
He later served as President and Board Member of Continuous Curve Contact Lens, Inc.,
an industry-leading public company that was acquired by Revlon in 1980.
Jim received a Bachelor of Science degree from the University of Wisconsin and a Doctor
of Optometry degree from Pacific University. Jim also served with the U.S. Army in the
Counter Intelligence Corps.
Dr. Berglund is actively involved in several philanthropic boards. He serves as a Trustee
of Pacific University and together with his wife Mary endowed the Berglund Center for
Internet Studies (BCIS) at Pacific University
Exactly!!
That's good news Merlin, thanks for your efforts
New CEO? He has been CEO for a while already
However it is good news that there is some kind of insider buying
Is there any aproval needed in that part of the world?
Maybe things are not that bad or in other words FINAL
Rereading the report:
"We are pleased that the PFS results for the bavituximab-containing arm by both local and central image interpretation actually met or exceeded our expectations going into the study. While the data from the investigator assessments..."
And "Progression-free survival (PFS) denotes the chances of staying free of disease progression for a group of individuals suffering from a cancer after a particular treatment. It is the percentage of individuals in the group whose disease is likely to remain stable (and not show signs of progression) after a specified duration of time."
So I agree with you MOJO that this may be an interpretation matter. However OS will tell who was right.
How precise the local and central image interpretation is? That is the question
""We are pleased that the PFS results for the bavituximab-containing arm by both local and central image interpretation actually met or exceeded our expectations going into the study."
How can they say that ??
Merlin what is your take on...?
I find it a bit excesive
Form 8-K for APRICUS BIOSCIENCES, INC.
8-Mar-2012
Change in Directors or Principal Officers
Item 5.02. Departure of Directors or Principal Officers; Election of Directors; Appointment of Principal Officers
On March 5, 2012, the Compensation Committee of the Board of Directors of Apricus Biosciences, Inc. (the "Company") approved (i) annual increases in the base salaries for those officers identified below and (ii) the payment of annual cash bonus awards for fiscal 2011 for the same officers. Salary increases were effective as of January 1, 2012, which was the start of the current fiscal year.
Name Title New Salary Bonus Payment
Bassam Damaj, Ph.D President and Chief Executive Officer $463,950 $180,000
Senior Vice President and Chief Financial
Steven Martin(1) Officer $268,060 $42,467
Executive Vice President, General Counsel
Randy Berholtz and Secretary $257,750 $60,000
Edward Cox Vice President Corporate Development and $180,000 $38,400
Investor Relations
(1) Mr. Martin was appointed our Senior Vice President and Chief Financial Officer effective June 2, 2011, and accordingly received a pro rated bonus payment for fiscal 2011.
http://biz.yahoo.com/e/120308/apri8-k.html
APRI to Ring The NASDAQ Stock Market Closing Bell
that will be tomorrow
will that be any good for the PPS?
I dont agree with you... if we lose at the CAFC we only have to wait for the ITC in fall
I have been invested in APRI & NextA just before APRI was created
I have listened (watched) most of the C.C. & videos from D.B.... and I find him to be a peculiar character... like a very astute person...
The fact that he has shown (till recently) a lot of care for the PPS tells me that in spite of the latest events... he is working around the way to make PPS go up.
It is not that other CEOs don't care... but I have to admit that for this guy that's an important issue and makes plans in that regard
JMO
I think I will aply for it... and will find out what is going on LOL
keep you informed
My best advice is that you go to the Company website...
You have plenty of interviews and presentations under Investors/webcasts and news... wher you can gather info
http://www.internationalstemcell.com/news.htm
The tech seems to be very impressive and unique... if they can survive till stem cells technology (in general blooms) I believe they will make a difference
good luck
<<Cure of...>>
Well I guess Chemotherapy (in some percentages) also cures some cancers
So I guess that the name of the game is how big that percentage is...
Or you think that "Cure" means 100% of the cases?
Yes IV is working... but maybe your question was for NukeJohn
Thanks Merlin... maybe your post should make it as a sticky one
One comment regarding the USA and Vitaros... I thought that APRI would get no royalties... I suppose they would get some money from production and for the special case Vitaros seems to need (temperature issues)
Around 3 times more people live in Germany than in Canada... and we are up only a 5%?
So Italy & Germany down... who is next?
France, U.K., Spain, Holland, Belgium, Sweeden, Norway, Finland, Denmark, Ireland, Austria, Portugal, Greece, all Eastern European Countries... Wow that is a lot for future good news...
The news is HUGE... I don't care if I am considered a pumper...
I live in Europe and I see that APRI has taken the approach of licensing... on a country by country basis which I suppose will give them better contracts
We are talking of a market which can be around 50% bigger than the US market (population-wise)
Thanks Merlins... My main question right now is will APRI have to wait those extra 30 days to announce the end of the finacial operation? or not?
I wish somebody could clairfy this point
Dont get me wrong... I love to hear from management, but isn't it strange that mgmt has the time and energy to talk to us retail investors...?
Don't they have anything better to do?
This makes me worry
Ready to listen to the webcast of the Conference...
Let's see!!!
I just bought more @ $3.65
I use Lichello' s method that said BUY now!!! but I think I would have done it anyways...
Dont understand the shorts!!!
... If so, this is a huge opportunity I am not going to miss
Thanks for the info
JR, RE. your third possibility
Why would someone who is trying to get out of a large position sticks to sell at 1.02?? why those chances of getting out at 1.03 or higher were not allowed? Shouldnt his/her priority be making the best possible deal?
Maybe some trading expert kindly cares to explain
thanks
thanks Drano for your reply
Regarding ISCO... right now we are waiting for the lifeskin sales
If they are good this could be a pivotal point
otherwise we would need more patience but I am sure that if stemcells tech ever takes off... ISCO will be an important player there
For the time being I hold to my shares!
The quote Dranos mentions is been there ever since (in the Parthenogenesis Section)... so it is not any news to be concerned about (IMHO).
And you are right there were talking about 50 lines (certainly not more than 100) to cover the whole human spectrum. They were expecting to finish it in a few more years
Furthermore...Two paragraphs above they say:
"Different activation techniques applied to human oocytes allow the creation of either HLA heterozygous human parthenogenetic stem cell lines (hpSC), which are exactly HLA-matched/ histocompatible with the oocyte donors, or HLA homozygous hpSC, which may be histocompatible with significant segments of the human population."
And of course ... even so it is LIMITED to a fraction of the human population
Hi Drano, which other boards are you talking about?
I am trying to follow ISCo -I am also an investor who bought some time ago :(... and I would be interested in checking that other board
thanks
Is Synopec in the plans?
Very interesting post from Valdo (Yahoo)
http://messages.finance.yahoo.com/Stocks_%28A_to_Z%29/Stocks_S/threadview?m=tm&bn=24523&tid=110339&mid=110472&tof=15&frt=2
If you look at SYNM's "Oil & Gas Investor Presentation (which I recommend every SYNM investor to do), you'll see SYNM's plan to scale up barrels per day on slide #17 from 2500 bpd in 2012, to 3000 bpd in 2013 (from debottlenecking and expanding G1), to 6000 BPD in 2014 (opening G2), to 11,000 BPD in 2015 (G1, G2, & opening GTL plant #1).
The slide also shows they expect 50% of the 10K BPD GTL plant, so there will be a JV with deep pockets as the 10K BPD GTL plant is expected to cost $750-$850M.
As the original poster surmised, its a good bet that Sinopec looks to play the GTL game and use SYNM to get their foot in the USA door. They just bought a 33% stake in Devon Energy's 5 shale gas fields located where--near Geismar's back yard...
Thanks Merlin for the link...
Little grains of sand here and there can make a difference.
What about approval of Vitaros in Europe? I think those 240 days (average waiting) may be just around the corner
This is a link to hear APRI presentation last Jan 9th at Biotech Showcase 2012
http://www.media-server.com/m/p/utydmuv9
I thought it was pretty good and encouraging... I still dont understand how it took a dive after they announced the ABT deal
But well market is tricky... Patience!!